BRIEF published on 05/07/2025 at 15:25, 1 year 4 months ago Transition de direction chez Carl Zeiss Meditec AG Carl Zeiss Meditec Changement De Direction Ophtalmologie Maximilien Foerst Dr Markus Weber
BRIEF published on 05/07/2025 at 15:25, 1 year 4 months ago Leadership Transition at Carl Zeiss Meditec AG Carl Zeiss Meditec Leadership Change Ophthalmology Maximilian Foerst Dr. Markus Weber
PRESS RELEASE published on 05/07/2025 at 15:20, 1 year 4 months ago Change of President and CEO at Carl Zeiss Meditec AG Carl Zeiss Meditec AG announces change of President and CEO: Dr. Markus Weber steps down on 31 May 2025, to be succeeded by Maximilian Foerst on 1 June 2025. Foerst is currently Head of ZEISS Greater China Carl Zeiss Meditec AG President CEO Change Maximilian Foerst
BRIEF published on 05/07/2025 at 14:41, 1 year 4 months ago Changement de direction chez Carl Zeiss Meditec AG Changement De Direction Carl Zeiss Meditec AG Maximilien Foerst Stabilité De La Gestion Marché De La Grande Chine
BRIEF published on 05/07/2025 at 14:41, 1 year 4 months ago Leadership Change at Carl Zeiss Meditec AG Carl Zeiss Meditec AG Leadership Change Maximilian Foerst Management Stability Greater China Market
PRESS RELEASE published on 05/07/2025 at 14:36, 1 year 4 months ago EQS-Adhoc: Change of President and CEO at Carl Zeiss Meditec AG Carl Zeiss Meditec AG announces change of President and CEO, Dr. Markus Weber, to be succeeded by Maximilian Foerst. Handover on May 31, 2025. Foerst appointed as new Executive Board member of Carl Zeiss AG Carl Zeiss Meditec AG President CEO Change Maximilian Foerst
BRIEF published on 04/15/2025 at 09:02, 1 year 4 months ago Carl Zeiss Meditec annonce de solides résultats au deuxième trimestre 2024/25 Croissance Des Revenus Marché Chinois Chirurgie Réfractive Résultats Du Deuxième Trimestre 2024/25 Augmentation De L'EBITA
BRIEF published on 04/15/2025 at 09:02, 1 year 4 months ago Carl Zeiss Meditec Reports Strong Q2 Earnings for 2024/25 Revenue Growth Refractive Surgery China Market Q2 2024/25 Earnings EBITA Increase
PRESS RELEASE published on 04/15/2025 at 08:57, 1 year 4 months ago EQS-Adhoc: Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25 Carl Zeiss Meditec AG achieves significant earnings increase in Q2 2024/25, with revenue of EUR 560 million and EBITA of EUR 78 million Revenue Growth Carl Zeiss Meditec AG Earnings Increase EBITA Q2 2024/25
BRIEF published on 02/27/2025 at 10:43, 1 year 6 months ago Le ZEISS VISUMAX 800 obtient l'approbation de la Chine Marché Chinois Approbation Réglementaire ZEISS VISUMAX 800 Laser Femtoseconde Amélioration Chirurgicale
Published on 09/12/2026 at 02:35, 11 hours 25 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 55 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 35 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 29 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 45 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 49 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 15 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 44 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
